Status:
COMPLETED
Retrospective Study of Patients With Severe Aplastic Anemia Who Relapsed After Immunosuppressive Therapy
Lead Sponsor:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Severe Aplastic Anemia
Eligibility:
All Genders
2+ years
Brief Summary
Background: Severe aplastic anemia (SAA) is a form of bone marrow failure. It usually results from a cytotoxic T cell attack on the marrow stem cell. Two treatments can be used for most people with ...
Detailed Description
Severe aplastic anemia (SAA) is a form of bone marrow failure and in most cases is the result of a cytotoxic T cell attack on the marrow stem cell. It is effectively treated in most patients with eith...
Eligibility Criteria
Inclusion
- This is a retrospective chart review. The investigators will review the medical records of adults and children with severe aplastic anemia (SAA) enrolled on immunosuppressive therapy (IST) treatment protocols in the NHLBI.
- Patients who opted out of future use of data on their prior studies will be excluded from this study.
Exclusion
Key Trial Info
Start Date :
June 15 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 15 2023
Estimated Enrollment :
173 Patients enrolled
Trial Details
Trial ID
NCT04436380
Start Date
June 15 2020
End Date
March 15 2023
Last Update
March 16 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Heart, Lung and Blood Institute (NHLBI)
Bethesda, Maryland, United States, 20892